New approaches to structure-based discovery of dengue protease inhibitors.

@article{Tomlinson2009NewAT,
  title={New approaches to structure-based discovery of dengue protease inhibitors.},
  author={S. Tomlinson and R. D. Malmstrom and S. Watowich},
  journal={Infectious disorders drug targets},
  year={2009},
  volume={9 3},
  pages={
          327-43
        }
}
Dengue virus (DENV), a member of the family Flaviviridae, presents a tremendous threat to global health since an estimated 2.5 billion people worldwide are at risk for epidemic transmission. DENV infections are primarily restricted to sub-tropical and tropical regions; however, there is concern that the virus will spread into new regions including the United States. There are no approved antiviral drugs or vaccines to combat dengue infection, although DENV vaccines have entered Phase 3 clinical… Expand
Ten years of dengue drug discovery: progress and prospects.
Peptides as Therapeutic Agents for Dengue Virus
Anthracene-based inhibitors of dengue virus NS2B-NS3 protease.
New developments in flavivirus drug discovery
  • W. M. Kok
  • Biology, Medicine
  • Expert opinion on drug discovery
  • 2016
Molecular herbal inhibitors of Dengue virus: an update
Pharmacophoric characteristics of dengue virus NS2B/NS3pro inhibitors: a systematic review of the most promising compounds
Natural Products as Source of Potential Dengue Antivirals
...
1
2
3
4
5
...

References

SHOWING 1-3 OF 3 REFERENCES
Discovering Dengue DrugsFig
  • www.worldcommunitygrid.org)
  • 2008
Flaviviridae: The Viruses and Their Replication, in Fundamental Virology, 4th Ed
  • 2001